Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Affiliations

Science Blogs
ACI Profile for Alan Kotok
Featured in Alltop

Liquid Biopsy Company Gains $360M for Cancer Sequencing

A company using blood tests to diagnose cancer is receiving a $360 million investment for its campaign to sequence DNA from 1 million people at high risk of cancer. . . . → Read More: Liquid Biopsy Company Gains $360M for Cancer Sequencing

Grid Computing Harnessed for Childhood Cancer Research

An international consortium is seeking crowdsourced computing power to screen drug candidates for treating a number of cancers affecting children. . . . → Read More: Grid Computing Harnessed for Childhood Cancer Research

Biotech, Pharma Partner on Neuro Drug Discovery

A collaboration between a biotechnology enterprise tracking defective proteins and pharmaceutical company plans to discover new treatments for neurodegenerative disorders. . . . → Read More: Biotech, Pharma Partner on Neuro Drug Discovery

Stem Cell Therapy Company Formed, Staked to $225M

A pharmaceutical company and health care venture investor are forming BlueRock Therapeutics, a biotechnology enterprise to design regenerative medicine treatments with stem cells. . . . → Read More: Stem Cell Therapy Company Formed, Staked to $225M

Ostrich Antibodies to Fight Resistant Infections

A biotechnology company developing antibodies grown in ostrich eggs is partnering with a Boston hospital to test a new treatment for Clostridium difficile, or C. difficile, a stubborn infection, increasingly resistant to antibiotics, and often contracted in hospitals. . . . → Read More: Ostrich Antibodies to Fight Resistant Infections

Takeda Awarded $19.8 Million for Zika Vaccine

Takeda Pharmaceutical Company is receiving $19.8 million from a U.S. public health agency for initial steps to develop a vaccine to prevent Zika infections. . . . → Read More: Takeda Awarded $19.8 Million for Zika Vaccine

Spacecraft Returns with Space Station Research Samples

A SpaceX Dragon spacecraft returned today with samples from several biomedical research studies conducted by astronauts on the International Space Station. . . . → Read More: Spacecraft Returns with Space Station Research Samples

Hemophilia Therapy Candidate Given Breakthrough Status

(Public Domain Pictures/Pixabay)

4 September 2015. A synthetic antibody designed to prevent bleeding episodes among people with the most common type of hemophilia received a breakthrough therapy designation from the U.S. Food and Drug Administration. The pharmaceutical company Roche says FDA assigned the designation its biologic therapy code-named ACE910, now being tested in clinical . . . → Read More: Hemophilia Therapy Candidate Given Breakthrough Status

Spin-Off Biotech Formed for Autoimmune Disorders

(Centers for Disease Control and Prevention)

2 June 2015. Drug maker Astellas Pharma Inc. in Tokyo and Anokion SA, a biotechnology company in Lausanne, Switzerland, are forming Kanyos Bio Inc., a spin-off enterprise to develop therapy candidates for autoimmune diseases. The deal could bring Kanyos Bio, based in Cambridge, Massachusetts, as much as $760 . . . → Read More: Spin-Off Biotech Formed for Autoimmune Disorders

Astellas Getting First Access to Leukemia Antibody

Acute myeloid leukemia cells (Cancer Genome Atlas)

3 April 2015. MD Anderson Cancer Center in Houston is granting Astellas Pharma Inc. in Tokyo an option to license MD Anderson’s discovery of a synthetic antibody showing promise as a treatment for acute myeloid leukemia. For the licensing option, MD Anderson could earn up to $26 . . . → Read More: Astellas Getting First Access to Leukemia Antibody